The anxiolytic effect of γ-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil

European Journal of Pharmacology

Volumn 342, Issue 1, 1998, Pages 21-27

  Schmidt Mutter, Catherine ^a,b   Pain, Laure ^b,c   Sandner, Guy ^c   Gobaille, Serge ^a   Maitre, Michel ^a  

^a CENTRE DE NEUROCHIMIE   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c INSERM   (France)

Author keywords

Anxiety; Elevated plus maze; Flumazenil; GHB ( hydroxybutyrate); Locomotor activity

Indexed keywords

4 HYDROXYBUTYRIC ACID; ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; DIAZEPAM; FLUMAZENIL; NALOXONE; NCS 382; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; BENZOCYCLOHEPTENES; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUMAZENIL; GABA MODULATORS; MALE; MOTOR ACTIVITY; NALOXONE; NARCOTIC ANTAGONISTS; RATS; SODIUM OXYBATE;

EID: 0032545654     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01503-3     Document Type: Article

References (35)

1. Agmo A., Galvan A., Heredia A., Morales M. Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: Experimental studies and literature review. Psychopharmacology. 120:1995;186-194.
2. Assié M.B., Chopin P., Stenger A., Palmier C., Briley M. Neuropharmacology of a new potential anxiolytic compound, F2692, 1-(3′-trifluoromethyl phenyl) 1,4-dihydro-3-amino-4-oxo-6-methyl pyridazine: 1. Acute and in vivo effects. Psychopharmacology. 110:1993;13-18.
3. B) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): A possible mechanism for the generation of absence-like seizures induced by GHB. J. Pharmacol. Exp. Ther. 273:1995;1534-1543.
4. Chopin P., Briley M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology. 110:1993;409-414.
5. Costa E., Guidotti A. Minireview: Diazepam binding inhibitor (DBI), a peptide with multiple biological activities. Life Sci. 49:1991;325-344.
6. De Feudis F.V., Collier B. Conversion of γ-hydroxybutyrate to γ-aminobutyrate by mouse brain in vivo. Experientia. 26:1970;1072-1073.
7. Devoto P., Colombo G., Cappai F., Gessa G.L. Naloxone antagonizes ethanol- but not gamma-hydroxybutyrate-induced sleep in mice. Eur. J. Pharmacol. 252:1994;321-324.
8. Engel J.A., Egbe P., Liljequist S., Söderpalm B. Effects of amperozide in two animal models of anxiety. Pharmacol. Toxicol. 64:1989;452-456.
9. File S.E., Pellow S. The anxiolytic but not the sedative properties of tracazolate are reversed by the benzodiazepine receptor antagonist, RO 15-1788. Neuropsychobiology. 14:1985;193-197.
10. Gallimberti L., Cibin M., Pagnin P., Sabbion R., Pani P.P., Piratsu R., Ferrara S.D., Gessa G.L. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. Neuropsychopharmacology. 9:1993;77-81.
11. Gerra G., Caccavari R., Fontanesi B., Marcato A., Fertonani Affini G., Maestri D., Avanzini P., Lecchini R., Delsignore R., Mutti A. Flumazenil effects on growth hormone response to gamma-hydroxybutyric acid. Int. Clin. Psychopharmacol. 9:1994;211-215.
12. Gerra G., Caccavari R., Fontanesi B., Fertonani Affini G., Maestri D., Avanzini P., Zaimovic A., Franchini D., Delsignore R. Naloxone and metergoline effects on growth hormone response to gamma-hydroxybutyric acid. Int. Clin. Psychopharmacol. 10:1995;245-250.
13. Gobaille S., Schmidt C., Cupo A., Herbrecht F., Maitre M. Characterization of methionine-enkephalin release in the rat striatum by in vivo dialysis: Effects of gamma-hydroxybutyrate on cellular and extra-cellular methionine-enkephalin levels. Neuroscience. 60:1994;637-648.
14. Hechler V., Bourguignon J.J., Wermuth C.G., Mandel P., Maitre M. γ-Hydroxybutyrate uptake by rat brain striatal slices. Neurochem. Res. 10:1985;387-396.
15. Hechler V., Gobaille S., Bourguignon J.J., Maitre M. Extracellular events induced by gamma-hydroxybutyrate in striatum: A microdialysis study. J. Neurochem. 56:1991;938-944.
16. Hösli L., Hösli E., Lehmann R., Schneider J., Borner M. Action of γ-hydroxybutyrate and GABA on neurones of cultured rat central nervous system. Neurosci. Lett. 37:1983;257-260.
17. Hunkeler W., Mohler H., Pieri L., Polc P., Bonetti E.P., Cumin R., Schaffner R., Haefely W. Selective antagonists of benzodiazepines. Nature. 290:1981;514-516.
18. Laborit H. Sodium 4-hydroxybutyrate. Int. J. Neuropharmacol. 3:1964;433-452.
19. Maitre M. The γ-hydroxybutyrate signalling system in brain: Organization and functional implications. Prog. Neurobiol. 51:1997;337-361.
20. Maitre M., Hechler V., Vayer Ph., Gobaille S., Cash C.D., Schmitt M., Bourguignon J.J. A specific γ-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. J. Pharmacol. Exp. Ther. 255:1990;657-663.
21. Nagatani T., Yamamoto T., Takao K., Hashimoto S., Kasahara K., Sugihara T., Ueki S. Pharmacological profile of a potential anxiolytic: AP159, a new benzothieno-pyridine derivative. Psychopharmacology. 104:1991;432-438.
22. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
23. Privette T.H., Terrian D.M. Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacology. 118:1995;444-450.
24. Sayin Ü., Purali N., Özkan T., Altug T., Büyükdevrim S. Vigabatrin has an anxiolytic effect in the elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 43:1992;529-535.
25. Schmidt C., Gobaille S., Hechler V., Schmitt M., Bourguignon J.J., Maitre M. Anti-sedative and anti-cataleptic properties of NCS-382, a γ-hydroxybutyrate receptor antagonist. Eur. J. Pharmacol. 203:1991;393-397.
26. A receptor complex in the rat cerebral cortex. Psychopharmacology. 104:1991;351-355.
27. Shekhar A. GABA receptors in the region of the dorsomedial hypothalamus of rats mediate anxiety in the elevated plus-maze test. I. Behavioral measures. Brain Res. 627:1993;9-16.
28. Sherif F., Harro J., El-Hwuegi A., Oreland L. Anxiolytic-like effect of the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA) on rat exploratory activity. Pharmacol. Biochem. Behav. 49:1994;801-805.
29. Snead O.C., Bearden L.J. Naloxone overcomes the dopaminergic EEG and behavioral effects of γ-hydroxybutyrate. Neurology. 30:1980;832-838.
30. A receptor function in the gamma-hydroxybutyrate model of generalized absence seizures. Neuropharmacology. 32:1993;401-409.
31. Snead O.C., Nichols A.C. Gamma-hydroxybutyric acid binding sites: Evidence for coupling to a chloride anion channel. Neuropharmacology. 26:1987;1519-1523.
32. Snead O.C., Nichols A.C., Liu C.C. γ-Hydroxybutyric acid binding sites: Interaction with the GABA-benzodiazepine-picrotoxin receptor complex. Neurochem. Res. 17:1992;201-204.
33. Tsuda M., Suzuki T., Misawa M., Nagase H. Involvement of the opioid system in the anxiolytic effect of diazepam in mice. Eur. J. Pharmacol. 307:1996;7-14.
34. Vayer P., Mandel P., Maitre M. Conversion of γ-hydroxybutyrate to γ-aminobutyrate in vitro. J. Neurochem. 45:1985;810-814.
35. Zerbib R., Pierrefiche G., Ferran C., Laborit H. Potential antidepressant activity of gamma-hydroxybutyrate in the mouse 'behavioral despair' test: Correlation with the central dopaminergic system. Res. Commun. Psychol. Psychiatr. Behav. 17:1992;109-122.